A Safety and Efficacy Study of Bimatoprost 0.01% in Primary Open-Angle Glaucoma (POAG) or Ocular Hypertension (OH)
Phase 4
Completed
- Conditions
- Interventions
- First Posted Date
- 2012-05-09
- Last Posted Date
- 2014-01-28
- Lead Sponsor
- Allergan
- Target Recruit Count
- 800
- Registration Number
- NCT01594970
A Study of Lumigan® 0.01% in Patients With Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT)
Completed
- Conditions
- Interventions
- First Posted Date
- 2012-05-02
- Last Posted Date
- 2014-06-13
- Lead Sponsor
- Allergan
- Target Recruit Count
- 419
- Registration Number
- NCT01589510
Safety and Tolerability of AGN-199201 in Patients With Erythema Associated With Rosacea
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2012-04-17
- Last Posted Date
- 2019-11-18
- Lead Sponsor
- Allergan
- Target Recruit Count
- 64
- Registration Number
- NCT01579084
BOTOX® Treatment in Adult Patients With Post-Stroke Lower Limb Spasticity
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2012-04-11
- Last Posted Date
- 2016-09-28
- Lead Sponsor
- Allergan
- Target Recruit Count
- 468
- Registration Number
- NCT01575054
A Safety and Efficacy Study to Assess OZURDEX® in Patients With Macular Oedema Secondary to Retinal Vein Occlusion (RVO)
Completed
- Conditions
- Interventions
- First Posted Date
- 2012-04-05
- Last Posted Date
- 2019-04-19
- Lead Sponsor
- Allergan
- Target Recruit Count
- 573
- Registration Number
- NCT01571557
Observational Study of Lumigan® 0.01% for Treatment of Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT)
Completed
- Conditions
- Interventions
- First Posted Date
- 2012-04-02
- Last Posted Date
- 2013-09-20
- Lead Sponsor
- Allergan
- Target Recruit Count
- 933
- Registration Number
- NCT01568008
Post Market Surveillance of OZURDEX® for Branch Retinal Vein Occlusion (BRVO) and Central Retinal Vein Occlusion (CRVO)
- First Posted Date
- 2012-04-02
- Last Posted Date
- 2015-02-10
- Lead Sponsor
- Allergan
- Target Recruit Count
- 100
- Registration Number
- NCT01568021
Retrospective Data Collection Study in Patients Receiving Two or More OZURDEX® Injections for Macular Oedema Secondary to Retinal Vein Occlusion
Completed
- Conditions
- Interventions
- First Posted Date
- 2012-03-29
- Last Posted Date
- 2013-05-27
- Lead Sponsor
- Allergan
- Target Recruit Count
- 26
- Registration Number
- NCT01566526
Safety and Efficacy of LUMIGAN® RC Versus DuoTrav® in Patients Who Require Further Intraocular Pressure (IOP) Reduction
- First Posted Date
- 2012-03-08
- Last Posted Date
- 2014-08-15
- Lead Sponsor
- Allergan
- Target Recruit Count
- 135
- Registration Number
- NCT01547598
Study Comparing Quantitative Assessments in Open-angle Glaucoma (OAG) and/or Ocular Hypertension (OHT)
- First Posted Date
- 2012-02-28
- Last Posted Date
- 2013-09-19
- Lead Sponsor
- Allergan
- Target Recruit Count
- 102
- Registration Number
- NCT01540370
© Copyright 2024. All Rights Reserved by MedPath